Gastroenterología y Hepatología (English Edition)最新文献

{"title":"Asociación Española de Neurogastroenterología y Motilidad (ASENEM) updated review on the management of functional abdominal pain","authors":"Jordi Serra ,&nbsp;Ariadna Aguilar ,&nbsp;Elizabeth Barba ,&nbsp;Constanza Ciriza de los Ríos ,&nbsp;Laura Garcia Pravia ,&nbsp;Vicente Martínez ,&nbsp;Blanca Serrano Falcón","doi":"10.1016/j.gastre.2024.04.072","DOIUrl":"10.1016/j.gastre.2024.04.072","url":null,"abstract":"<div><div>Functional abdominal pain is a disorder in which central and peripheral sensitization processes converge, leading to hypersensitivity and allodynia. Differential diagnosis is made with organic digestive, renal, gynecological, endocrine, or neurological diseases. Treatment should be individualized for each patient. In cases of debilitating pain, therapy combining drugs with different mechanisms of action can be initiated, while in less severe cases, therapy with a progressive introduction of drugs based on clinical response is advised. The first line includes general lifestyle advice and antispasmodic substances, like peppermint oil, anticholinergic/antimuscarinic, and calcium channels antagonists. In the second line of treatment, neuromodulating agents are added. Finally, when these measures fail, third-line treatments such as gabapentine and atypical antipsychotics are considered. Psychological interventions should be considered if specialized therapists are available to manage these disorders.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 888-900"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of Lactate Ringer's solution versus Normal Saline in the treatment of acute pancreatitis","authors":"Zhengwang Wang ,&nbsp;Keru Shi ,&nbsp;Shaojian Mo ,&nbsp;Ziang Liu ,&nbsp;Jie Yao","doi":"10.1016/j.gastre.2024.04.049","DOIUrl":"10.1016/j.gastre.2024.04.049","url":null,"abstract":"<div><div>Fluid resuscitation is an important way in the treatment of acute pancreatitis (AP). This meta-analysis aimed to compare the safety and efficacy of Lactate Ringer's solution (LR) and Normal Saline (NS) in the treatment of patients with acute pancreatitis. Searched in PubMed, Web of Science Core Collection (Clarivate), Embase, Cochrane Library, CNKI, China Wanfang, and China VIP database. All randomized controlled clinical trials (RCTs) were identified. Six studies with 431 patients were included. Compared with NS, LR can significantly reduce the incidence of SIRS at 24<!--> <!-->h, reduce the length of hospitalization, moderate–severe AP, ICU admission and local complications, especially pancreatic necrosis. It is safe and effective to choose LR for fluid resuscitation in AP, but due to the small number of included studies, multi-center and large-sample RCTs are still needed for further verification.</div><div>PROSPERO registration number: CRD42022322788.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 876-887"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study","authors":"Gonzalo Latorre ,&nbsp;José Ignacio Vargas ,&nbsp;Shailja C. Shah ,&nbsp;Danisa Ivanovic-Zuvic ,&nbsp;Pablo Achurra ,&nbsp;Martín Fritzsche ,&nbsp;Jai-Sen Leung ,&nbsp;Bernardita Ramos ,&nbsp;Elisa Jensen ,&nbsp;Javier Uribe ,&nbsp;Isabella Montero ,&nbsp;Vicente Gandara ,&nbsp;Camila Robles ,&nbsp;Miguel Bustamante ,&nbsp;Felipe Silva ,&nbsp;Eitan Dukes ,&nbsp;Oscar Corsi ,&nbsp;Francisca Martínez ,&nbsp;Victoria Binder ,&nbsp;Roberto Candia ,&nbsp;Arnoldo Riquelme","doi":"10.1016/j.gastre.2024.04.038","DOIUrl":"10.1016/j.gastre.2024.04.038","url":null,"abstract":"<div><h3>Background</h3><div>The updated Sydney system biopsy protocol (USSBP) standardizes the sampling of gastric biopsies for the detection of preneoplastic conditions (<em>e.g.</em>, gastric intestinal metaplasia [GIM]), but the real-world diagnostic yield is not well-described.</div></div><div><h3>Aim</h3><div>To determine whether regular application of USSBP is associated with higher detection of chronic atrophic gastritis (CAG), GIM and autoimmune gastritis (AIG).</div></div><div><h3>Methods</h3><div>We performed a real-world retrospective study at an academic urban tertiary hospital in Chile. We manually reviewed medical records from consecutive patients undergoing esophagogastroduodenoscopy (EGD) from January to December 2017. Seven endoscopists who performed EGDs were categorized into two groups (USSBP ‘regular’ and USSBP ‘infrequent’) based on USSBP adherence, using minimum 20% adherence as the prespecified threshold. Multivariable logistic regression models were used to estimate the odds ratios (aOR) and 95% confidence intervals (CI) for the association between endoscopist groups and the likelihood of diagnosing CAG, GIM or AIG.</div></div><div><h3>Results</h3><div>1206 patients were included in the study (mean age: 58.5; 65.3% female). The USSBP regular group demonstrated a higher likelihood of detecting CAG (20% <em>vs</em>. 5.3%; aOR 4.03, 95%CI: 2.69–6.03), GIM (12.2% <em>vs.</em> 3.4%; aOR 3.91, 95%CI: 2.39–6.42) and AIG (2.9% <em>vs.</em> 0.8%; aOR 6.52, 95%CI: 1.87–22.74) compared to infrequent group. Detection of advanced-stage CAG (Operative Link for Gastritis Assessment stage III/IV) was significantly higher in the USSBP regular <em>vs.</em> infrequent group (aOR 5.84, 95%CI: 2.23–15.31).</div></div><div><h3>Conclusions</h3><div>Routine adherence to USSBP increases the detection rates of preneoplastic conditions, including CAG, GIM and AIG. Standardized implementation of USSBP should be considered in high gastric cancer risk populations.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 793-803"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chilean consensus by expert panel using the Delphi technique for primary and secondary prevention of gastric cancer","authors":"Óscar Corsi Sotelo ,&nbsp;Margarita Pizarro Rojas ,&nbsp;Antonio Rollán Rodríguez ,&nbsp;Verónica Silva Figueroa ,&nbsp;Raúl Araya Jofré ,&nbsp;María Ester Bufadel Godoy ,&nbsp;Pablo Cortés González ,&nbsp;Robinson González Donoso ,&nbsp;Eduardo Fuentes López ,&nbsp;Gonzalo Latorre Selvat ,&nbsp;Patricio Medel-Jara ,&nbsp;Diego Reyes Placencia ,&nbsp;Mauricio Pizarro Véliz ,&nbsp;María Jesús Garchitorena Marqués ,&nbsp;María Trinidad Zegers Vial ,&nbsp;Francisca Crispi Galleguillos ,&nbsp;Manuel A. Espinoza ,&nbsp;Arnoldo Riquelme Pérez","doi":"10.1016/j.gastre.2024.04.043","DOIUrl":"10.1016/j.gastre.2024.04.043","url":null,"abstract":"<div><h3>Introduction</h3><div>Gastric cancer (GC) is the first cause of cancer-related death in Chile and 6th in Latin America and the Caribbean (LAC). <em>Helicobacter pylori</em> (<em>H. pylori</em>) is the main gastric carcinogen, and its treatment reduces GC incidence and mortality. Esophageal-gastro-duodenoscopy (EGD) allows for the detection of premalignant conditions and early-stage GC. Mass screening programs for <em>H. pylori</em> infection and screening for premalignant conditions and early-stage GC are not currently implemented in LAC. The aim of this study is to establish recommendations for primary and secondary prevention of GC in asymptomatic standard-risk populations in Chile.</div></div><div><h3>Methods</h3><div>Two on-line synchronous workshops and a seminar were conducted with Chilean experts. A Delphi panel consensus was conducted over 2 rounds to achieve &gt;80% agreement on proposed primary and secondary prevention strategies for the population stratified by age groups.</div></div><div><h3>Results</h3><div>10, 12, and 12 experts participated in two workshops and a seminar, respectively. In the Delphi panel, 25 out of 37 experts (77.14%) and 28 out of 52 experts (53.85%) responded. For the population aged 16–34, there was no consensus on non-invasive testing and treatment for <em>H. pylori</em>, and the use of EGD was excluded. For the 35–44 age group, non-invasive testing and treatment for <em>H. pylori</em> is recommended, followed by subsequent test-of-cure using non-invasive tests (stool antigen test or urea breath test). In the ≥45 age group, a combined strategy is recommended, involving <em>H. pylori</em> testing and treatment plus non-invasive biomarkers (<em>H. pylori</em> IgG serology and serum pepsinogens I and II); subsequently, a selected group of subjects will undergo EGD with gastric biopsies (Sydney Protocol), which will be used to stratify surveillance according to the OLGA classification (Operative Link for Gastritis Assessment); every 3 years for OLGA III–IV and every 5 years for OLGA I–II.</div></div><div><h3>Conclusion</h3><div>A “test-and-treat” strategy for <em>H. pylori</em> infection based on non-invasive studies (primary prevention) is proposed in the 35–44 age group, and a combined strategy (serology and EGD) is recommended for the ≥45 age group (primary and secondary prevention). These strategies are potentially applicable to other countries in LAC.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 845-857"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and prevalence of inflammatory bowel diseases in a population from Buenos Aires, Argentina","authors":"Pablo Andrés Olivera ,&nbsp;María Laura Parks ,&nbsp;Deborah Pellegrini ,&nbsp;Bárbara Finn ,&nbsp;Ramiro Gutierrez ,&nbsp;Ignacio Zubiaurre ,&nbsp;Juan Lasa","doi":"10.1016/j.gastre.2024.04.039","DOIUrl":"10.1016/j.gastre.2024.04.039","url":null,"abstract":"<div><h3>Background</h3><div>Inflammatory bowel diseases (IBD) incidence and prevalence in Latin America have experienced a significant shift in the last decades. There is paucity of IBD epidemiologic data in Argentina.</div></div><div><h3>Aim</h3><div>To determine the incidence and prevalence of IBD between 2018 and 2022 of a population from the city of Buenos Aires.</div></div><div><h3>Materials and methods</h3><div>From January 1st, 2018 to December 31st, 2022, the total population of two healthcare insurances were studied. ‘Possible’ IBD cases were identified using the following information sources: IBD-unit patient databases; electronic medical record; central laboratory electronic database; histopathology electronic database; pharmacy electronic database. Age-adjusted incidence and prevalence rates for Crohn's disease (CD), ulcerative colitis (UC) and IBD were estimated based on the number of patients compared with the at-risk population and expressed per 100,000 subjects. Trends in IBD incidence and prevalence were estimated as annual percentage changes; we used Poisson regression modeling to calculate significance in these trends over time.</div></div><div><h3>Results</h3><div>Information source analysis rendered 172 possible cases, of which 82 cases of IBD were finally confirmed: 27.16% were CD and 72.84% were UC. Mean age-standardized incidence across the study period for IBD, CD and UC was 11.93 (11.28–12.55), 2.88 (2.65–3.07) and 9.05 (8.83–9.2) respectively. Point prevalence on December 31st, 2022 for IBD, UC and CD was 134 (95%CI 132.3–135.6), 98 (96.95–99.52) and 36 (35.69–36.4) respectively.</div></div><div><h3>Conclusions</h3><div>We found an incidence and prevalence of IBD in a population from Buenos Aires higher than those previously published in epidemiological studies in Argentina.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 804-812"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in adults. A brief review","authors":"Esteban Fuentes-Valenzuela ,&nbsp;Pedro Delgado-Guillena ,&nbsp;Raúl Velamazan-Sandalinas ,&nbsp;Javier Jiménez Sánchez ,&nbsp;Natalia García-Morales ,&nbsp;Jesús Barrio ,&nbsp;Alfredo J Lucendo","doi":"10.1016/j.gastre.2024.04.050","DOIUrl":"10.1016/j.gastre.2024.04.050","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 901-905"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beaver tail liver","authors":"David Villaescusa Arenas ,&nbsp;Elena Garrido Gómez ,&nbsp;Carlos Martín de Argila ,&nbsp;Carmen Díaz del Río ,&nbsp;Claudia Álvarez Varela ,&nbsp;Carmen García Huerta ,&nbsp;Ana Belén Agarrabeitia Casado ,&nbsp;Miguel García González ,&nbsp;Agustín Albillos Martínez","doi":"10.1016/j.gastre.2024.04.048","DOIUrl":"10.1016/j.gastre.2024.04.048","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 873-875"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)","authors":"Eugeni Domènech ,&nbsp;Andreea Ciudin ,&nbsp;José María Balibrea ,&nbsp;Eduard Espinet-Coll ,&nbsp;Fiorella Cañete ,&nbsp;Lilliam Flores ,&nbsp;Manuel Ferrer-Márquez ,&nbsp;Román Turró ,&nbsp;Alejandro Hernández-Camba ,&nbsp;Yamile Zabana ,&nbsp;Ana Gutiérrez","doi":"10.1016/j.gastre.2024.04.051","DOIUrl":"10.1016/j.gastre.2024.04.051","url":null,"abstract":"<div><div>Obesity is a multifactorial, chronic, progressive and recurrent disease considered a public health issue worldwide and an important determinant of disability and death. In Spain, its current prevalence in the adult population is about 24% and an estimated prevalence in 2035 of 37%. Obesity increases the probability of several diseases linked to higher mortality such as diabetes, cardiovascular disease, hyperlipidemia, arterial hypertension, non-alcoholic fatty liver disease, several types of cancer, or obstructive sleep apnea. On the other hand, although the incidence of inflammatory bowel disease (IBD) is stabilizing in Western countries, its prevalence already exceeds 0.3%. Paralleling to general population, the current prevalence of obesity in adult patients with IBD is estimated at 15%–40%. Obesity in patients with IBD could entail, in addition to its already known impact on disability and mortality, a worse evolution of the IBD itself and a worse response to treatments. The aim of this document, performed in collaboration by four scientific societies involved in the clinical care of severe obesity and IBD, is to establish clear and concise recommendations on the therapeutic possibilities of severe or type III obesity in patients with IBD. The document establishes general recommendations on dietary, pharmacological, endoscopic, and surgical treatment of severe obesity in patients with IBD, as well as pre- and post-treatment evaluation.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 906-923"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease—EXVEDOCOL","authors":"Viviana Parra ,&nbsp;Sandra Cifuentes ,&nbsp;Sandra Avendaño ,&nbsp;Enrique Ponce de León ,&nbsp;Cristian Florez ,&nbsp;Gustavo Reyes ,&nbsp;Fabian Puentes ,&nbsp;Manuel Ballesteros ,&nbsp;Edilberto Nuñez ,&nbsp;Federico Gómez ,&nbsp;Juan Ricardo Márquez","doi":"10.1016/j.gastre.2024.04.044","DOIUrl":"10.1016/j.gastre.2024.04.044","url":null,"abstract":"<div><h3>Background</h3><div>Real-world studies about the effectiveness and safety of vedolizumab (VDZ) in the treatment of inflammatory bowel disease (IBD) in Latin America are scarce. Our study describes the effectiveness and safety of VDZ in Colombian patients with IBD.</div></div><div><h3>Methods</h3><div>EXVEDOCOL (EXperience of VEDOlizumab in COLombia) was a retrospective, multicenter, observational study. Adults with IBD receiving a first dose of VDZ between July 2016 and October 2018 were included. The co-primary outcomes clinical response, and remission, were determined at week 14 and last visit during the maintenance phase (LVMP). The secondary outcomes, deep remission and loss of response were recorded at LVMP.</div></div><div><h3>Results</h3><div>Thirty-one patients (25 ulcerative colitis (UC), 6 Crohn's disease (CD)) were included. At week 14, clinical response was achieved by 87.1% (27/31) of the patients treated with VDZ, while loss of response was reported in 6.7% (2/30). The remission rate at week 14 was 65.5% (19/29) and 75.9% (22/29) at LVMP. Prior anti-TNF exposure was reported in 61.3% (19 patients) of whom 84.2% (16/19) achieved clinical response at week 14 and 89.5% (17/19) at LVMP. For anti-TNF naïve patients, clinical response was recorded in 91.7% (11/12) at week 14 and 100% (12/12) at LVMP.</div></div><div><h3>Conclusions</h3><div>High clinical remission rates and safety profile highlight VDZ as a valuable treatment option for IBD patients. Anti-TNF naïve patients may derive greater benefit from therapy. Studies with larger cohorts could confirm these findings.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 858-866"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study","authors":"Rodrigo Bremer Nones ,&nbsp;Eron Fabio Miranda ,&nbsp;Gustavo de Nardi Marçal ,&nbsp;Fernanda da Silva Barbosa Baraúna ,&nbsp;Marcela Rocha Loures ,&nbsp;Paula Cenira Senger ,&nbsp;Daniela Oliveira Magro ,&nbsp;Paulo Gustavo Kotze","doi":"10.1016/j.gastre.2024.04.036","DOIUrl":"10.1016/j.gastre.2024.04.036","url":null,"abstract":"<div><h3>Objectives</h3><p>In Latin America, experience with monitoring serum Infliximab (IFX) concentrations is scarce. Our study aimed to compare IFX serum concentrations between patients with active disease or in remission.</p></div><div><h3>Patients and methods</h3><p>A cross-sectional study was performed in patients with luminal Crohn's disease (CD) during maintenance treatment with IFX. Patients were classified as in remission or disease activity according to clinical scores and endoscopic, radiological, and laboratory markers. A comparison of IFX trough levels between the two groups was performed.</p></div><div><h3>Results</h3><p>80 CD patients were included [41 (51%) in remission and 39 (49%) with active disease]. In the analysis of general disease activity, the median serum levels of IFX in patients with remission and with active CD were 5.63 [0.03–14.40] vs. 3.84 [0.03–14.40] (<em>p</em> <!-->=<!--> <!-->0.287). Furthermore, there was no difference in serum IFX concentrations in endoscopic, radiological, and laboratory activities. Only in the clinical evaluation there was a significant difference in the median serum IFX levels between patients in remission and disease activity, 5.63 [0.03–14.40] vs. 2.14 [0.32–10.54] (<em>p</em> <!-->=<!--> <!-->0.042).</p></div><div><h3>Conclusions</h3><p>IFX serum concentrations during maintenance treatment were similar in patients with luminal CD in remission and general, endoscopic, radiological, and laboratory disease activity. Patients with clinically active disease had lower IFX concentrations than patients in remission.</p></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 7","pages":"Pages 711-720"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141979353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}